The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB 3235-Number: 0076

4.00

Estimated average

burden

hours per

response:

1. Issuer's Identity

CIK (Filer ID Number)

Previous
Names

None

Entity Type

0001422142 ZETA ACQUISITION CORP II X Corporation

Name of Issuer Limited Partnership

Aerpio Pharmaceuticals, Inc.

Limited Liability Company

Jurisdiction of
Incorporation/OrganizationGeneral Partnership
Business TrustDELAWAREOther (Specify)

Year of Incorporation/Organization

X Over Five Years Ago

Within Last Five Years (Specify Year)

Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer

Aerpio Pharmaceuticals, Inc.

Street Address 1 Street Address 2

9987 CARVER ROAD

City State/Province/Country ZIP/PostalCode Phone Number of Issuer

CINCINNATI OHIO 45242 (513) 985-1920

3. Related Persons

Last Name First Name Middle Name

Gardner Joseph

Street Address 1 Street Address 2

9987 Carver Road Suite 420

City State/Province/Country ZIP/PostalCode

Cincinnati OHIO 45242

Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Satter Muneer

Street Address 1 Street Address 2

9987 Carver Road Suite 420

City State/Province/Country ZIP/PostalCode

Cincinnati OHIO 45242

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last NameFirst NameMiddle NameWeissPaulM.Street Address 1Street Address 29987 Carver RoadSuite 420

City State/Province/Country

Cincinnati OHIO 45242

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

ZIP/PostalCode

Castelein Caley

Street Address 1 Street Address 2

9987 Carver Road Suite 420

City State/Province/Country ZIP/PostalCode

Cincinnati OHIO 45242

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Dalal Anupam

Street Address 1 Street Address 2

9987 Carver Road Suite 420

City State/Province/Country ZIP/PostalCode

Cincinnati OHIO 45242

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Prelack Steven

Street Address 1 Street Address 2

9987 Carver Road Suite 420

City State/Province/Country ZIP/PostalCode

Cincinnati OHIO 45242

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Khuong Chau

Street Address 1 Street Address 2

9987 Carver Road Suite 420

City State/Province/Country ZIP/PostalCode

Cincinnati OHIO 45242

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Dugel Pravin

Street Address 1 Street Address 2

9987 Carver Road Suite 420

City State/Province/Country ZIP/PostalCode

Cincinnati OHIO 45242

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Murphy James

Street Address 1 Street Address 2

9987 Carver Road Suite 420

City State/Province/Country ZIP/PostalCode

Cincinnati OHIO 45242

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Peters Kevin G.

Street Address 1 Street Address 2

9987 Carver Road Suite 420

City State/Province/Country ZIP/PostalCode

Cincinnati OHIO 45242

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Pakola Stephen

Street Address 1 Street Address 2

9987 Carver Road Suite 420

City State/Province/Country ZIP/PostalCode

Cincinnati OHIO 45242

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

4. Industry Group

Agriculture Health Care Retailing
Banking & Financial Services X Biotechnology Restaurants
Commercial Banking Health Insurance Technology

Insurance Health Insurance Technology
Insurance Hospitals & Physicians Computers

Investment Banking Pharmaceuticals Telecommunications
Pooled Investment Fund Other Health Care Other Technology

Is the issuer registered as Manufacturing Travel

an investment company under the Investment Company

Real Estate

Airlines & Airports

Act of 1940? Commercial Lodging & Conventions

Yes No Construction Tourism & Travel Services

Other Banking & Financial Services REITS & Finance Other Travel

ther Banking & Financial Services REITS & Finance Other Travel

Business Services Residential Other

Energy Other Real Estate

Energy Conservation
Environmental Services

Coal Mining

Electric Utilities

5. Issuer Size

Revenue Range	OR	Aggregate Net Asset Value Range
No Revenues		No Aggregate Net Asset Value
\$1 - \$1,000,000		\$1 - \$5,000,000
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000
Over \$100,000,000		Over \$100,000,000
X Decline to Disclose		Decline to Disclose
Not Applicable		Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

	Investment Company Act Section 3(c)		
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(1)	Section 3(c)(9)	
Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii)	Section 3(c)(2)	Section 3(c)(10)	
Rule 504 (b)(1)(iii)	Section 3(c)(3)	Section 3(c)(11)	
Rule 505	Section 3(c)(4)	Section 3(c)(12)	
X Rule 506(b)	Section 3(c)(5)	Section 3(c)(13)	
Rule 506(c) Securities Act Section 4(a)(5)	Section 3(c)(6)	Section 3(c)(14)	
(-)(-)	Section 3(c)(7)		

7. Type of Filing

X New Notice Date of First Sale 2017-03-15 First Sale Yet to Occur Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes X No

9. Type(s) of Securities Offered (select all that apply)

X Equity
Debt
Tenant-in-Common Securities
X Option, Warrant or Other Right to Acquire Another Security
Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security
Other Right to Acquire Security

Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?

Yes X No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

12. Sales Compensation

Recipient Raymond James & Associates, Inc. (Associated) Broker or Dealer X None None **Street Address 1** 880 CARILLON PARKWAY City ST. PETERSBURG State(s) of Solicitation (select all that apply) Check "All States" or check individual States ALABAMA ALASKA ARIZONA ARKANSAS CALIFORNIA COLORADO CONNECTICUT DELAWARE DISTRICT OF COLUMBIA FLORIDA GEORGIA HAWAII IDAHO ILLINOIS INDIANA IOWA KANSAS KENTUCKY LOUISIANA MAINE MARYLAND MASSACHUSETTS MICHIGAN MINNESOTA MISSISSIPPI MISSOURI MONTANA NEBRASKA NEVADA NEW HAMPSHIRE **NEW JERSEY** NEW MEXICO NEW YORK NORTH CAROLINA NORTH DAKOTA OHIO OKLAHOMA OREGON PENNSYLVANIA PUERTO RICO RHODE ISLAND

Recipient CRD Number None

705

(Associated) Broker or Dealer CRD Number X None

None

Street Address 2

State/Province/Country ZIP/Postal Code

FLORIDA 33716

All States Foreign/non-US

SOUTH CAROLINA
SOUTH DAKOTA
TENNESSEE
TEXAS
UTAH
VERMONT
VIRGINIA
WASHINGTON
WEST VIRGINIA
WISCONSIN
WYOMING

Recipient

National Securities Corporation

(Associated) Broker or Dealer X None

None

Street Address 1

ONE UNION SQUARE 600 UNIVERSITY STREET

City

SEATTLE

State(s) of Solicitation (select all that apply) dividual States

Recipient CRD Number None

7569

(Associated) Broker or Dealer CRD Number X None

None

Street Address 2

SUITE 2900

State/Province/Country ZIP/Postal Code

WASHINGTON 98101

All States Foreign/non-US

AL	ABAMA
AL	ASKA
AR	IZONA
AR	KANSAS
CA	LIFORNIA
CO	LORADO
CO	NNECTICUT
DE	LAWARE
DIS	STRICT OF COLUMBIA
FL	ORIDA
GE	ORGIA
HA	WAII
ID	АНО
ILI	LINOIS
INI	DIANA
Ю	WA
	NSAS
KE	NTUCKY
LO	UISIANA
MA	AINE
MA	ARYLAND
MA	ASSACHUSETTS
MI	CHIGAN
MI	NNESOTA
MI	SSISSIPPI
MI	SSOURI
MC	ONTANA
NE	BRASKA
NE	VADA

NEW HAMPSHIR	E
NEW JERSEY	
NEW MEXICO	
NEW YORK	
NORTH CAROLIN	NΑ
NORTH DAKOTA	-
OHIO	
OKLAHOMA	
OREGON	
PENNSYLVANIA	
PUERTO RICO	
RHODE ISLAND	
SOUTH CAROLIN	ΙA
SOUTH DAKOTA	
TENNESSEE	
TEXAS	
UTAH	
VERMONT	
VIRGINIA	
WASHINGTON	
WEST VIRGINIA	
WISCONSIN	
WYOMING	

Recipient

Katalyst Securities LLC

(Associated) Broker or Dealer X None

None

Street Address 1

23-50 38TH ST

City

INDIANA IOWA KANSAS KENTUCKY LOUISIANA

ASTORIA

State(s) of Solicitation (select all that apply) ndividual States Recipient CRD Number None

112494

(Associated) Broker or Dealer CRD Number X None

None

Street Address 2

2ND FLOOR

State/Province/Country

ZIP/Postal Code

NEW YORK 11105

All States

Foreign/non-US

Check "All States" or check in
ALABAMA
ALASKA
ARIZONA
CALIFORNIA
COLORADO
CONNECTICUT
DELAWARE
DISTRICT OF COLUMBIA
FLORIDA
GEORGIA
IDAHO
ILLINOIS

MAINE
MARYLAND
MASSACHUSETTS
MICHIGAN
MINNESOTA
MISSISSIPPI
MISSOURI
NEVADA
NEW HAMPSHIRE
NEW JERSEY
NEW YORK
NORTH CAROLINA
NORTH DAKOTA
OHIO
OKLAHOMA
OREGON
PENNSYLVANIA
RHODE ISLAND
SOUTH CAROLINA
TEXAS
UTAH
VERMONT
VIRGINIA
WASHINGTON
WEST VIRGINIA
WISCONSIN

13. Offering and Sales Amounts

Total Offering Amount \$41,835,597 USD or Indefinite

Total Amount Sold \$41,835,597 USD

Total Remaining to be Sold \$0 USD or Indefinite

Clarification of Response (if Necessary):

A portion of the overall offering amount was comprised of warrants to purchase common stock of Aerpio Pharmaceuticals, Inc.

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

264

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$4,229,507 USD Estimate Finders' Fees \$0 USD Estimate

Clarification of Response (if Necessary):

A portion of the sales commissions paid included warrants to purchase common stock.

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Aerpio Pharmaceuticals, Inc.	/s/Joseph H. Gardner	Joseph H. Gardner	President & CEO	2017-03-30

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.